Dana-Farber/Brigham and Women's Cancer Center
Boston, MA, United States
Dr. Andrea K. Ng is Professor of Radiation Oncology at Dana-Farber/Brigham and Womens Cancer Center, Harvard Medical School. She is the Radiation Oncology Disease Site Lead for Hematologic Malignancies within the cancer center. Her clinical and research focus are on improving efficacy and reducing toxicity in the treatment of hematologic malignancies, and on the study of late effects of cancer therapy. As a member of the Steering Committee of the International Lymphoma Radiation Oncology Group (ILROG), Dr. Ng has contributed to the development of international guidelines on modern radiotherapy for Hodgkin and non-Hodgkin lymphoma, management of patients with relapsed/refractory lymphoma, and more recently, radiation therapy recommendations for hematologic malignancies during the COVID-19 pandemic. Dr. Ng has been serving on the ASTRO Annual Meeting Steering Committee since 2010. She has also served several leadership roles within ASTRO, including as Chair of the Annual Meeting Education Committee and Chair of Best of ASTRO. She is currently serving as Vice-Chair of the Annual Meeting Scientific Committee.
My clinical and academic areas of focus are in advancing novel radiation techniques and integrating radiation therapy with contemporary systemic therapy in the management of patients with hematologic malignancies. I have also contributed to refining and optimizing post-treatment monitoring strategies for lymphoma survivors. In the realm of education, I actively engage in mentoring and teaching trainees and faculty within my institution, as well as sharing insights and expertise through lectures delivered at various external institutions, and at national and international conferences. I have held leadership roles within professional organizations, where I have overseen educational and scientific programs, contributed to the board certification process, and played a pivotal role in guideline development on management of cancer survivors and radiotherapy applications in hematology oncology. On the administrative front, I lead initiatives geared towards fostering the professional growth and advancement of faculty members within my department and institution.
Disclosures:
Sunday, September 29, 2024
5:27 PM – 5:47 PM ET